Cytokines play a critical role in regulating immune responses and cellular behavior, with dual roles in both normal physiology and cancer pathology. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, and growth factors like TGF-β, VEGF, and EGF, can promote or inhibit tumor growth, influence the tumor microenvironment, and impact the efficacy of cancer treatments. Recent advances in targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate the immune system, inhibit tumor progression, and overcome resistance to conventional therapies. This review summarizes the current understanding and therapeutic implications of targeting cytokine and chemokine signaling pathways in cancer. By exploring the roles of these molecules in tumor biology and the immune response, the review highlights the development of novel therapeutic agents aimed at modulating these pathways to combat cancer. The review elaborates on the dual nature of cytokines as both promoters and suppressors of tumorigenesis, depending on the context, and discusses the challenges and opportunities this presents for therapeutic intervention. It also examines the latest advancements in targeted therapies, including monoclonal antibodies, bispecific antibodies, receptor inhibitors, fusion proteins, engineered cytokine variants, and their impact on tumor growth, metastasis, and the tumor microenvironment. Additionally, the review evaluates the potential of combining these targeted therapies with other treatment modalities to overcome resistance and improve patient outcomes. Furthermore, it focuses on ongoing research and clinical trials that are pivotal in advancing our understanding and application of cytokine- and chemokine-targeted therapies for cancer patients.Cytokines play a critical role in regulating immune responses and cellular behavior, with dual roles in both normal physiology and cancer pathology. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, and growth factors like TGF-β, VEGF, and EGF, can promote or inhibit tumor growth, influence the tumor microenvironment, and impact the efficacy of cancer treatments. Recent advances in targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate the immune system, inhibit tumor progression, and overcome resistance to conventional therapies. This review summarizes the current understanding and therapeutic implications of targeting cytokine and chemokine signaling pathways in cancer. By exploring the roles of these molecules in tumor biology and the immune response, the review highlights the development of novel therapeutic agents aimed at modulating these pathways to combat cancer. The review elaborates on the dual nature of cytokines as both promoters and suppressors of tumorigenesis, depending on the context, and discusses the challenges and opportunities this presents for therapeutic intervention. It also examines the latest advancements in targeted therapies, including monoclonal antibodies, bispecific antibodies, receptor inhibitors, fusion proteins, engineered cytokine variants, and their impact on tumor growth, metastasis, and the tumor microenvironment. Additionally, the review evaluates the potential of combining these targeted therapies with other treatment modalities to overcome resistance and improve patient outcomes. Furthermore, it focuses on ongoing research and clinical trials that are pivotal in advancing our understanding and application of cytokine- and chemokine-targeted therapies for cancer patients.